Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02557230|
Recruitment Status : Recruiting
First Posted : September 23, 2015
Last Update Posted : July 9, 2020
|Condition or disease|
|Genitourinary Neoplasms Neoplasms, Genitourinary|
Tumors of the kidney, bladder, prostate, testis, and adrenal represent a large part of the adult urologic practice, but are relatively infrequent in children.
Genitourinary tumors contribute to pediatric solid tumors. Wilms tumor, rhabdomyosarcoma, and germ cell tumors are the most common malignant genitourinary tumors in children.
The natural history and management of these tumors in the pediatric age is different from that of the adults. As result of the successful work of several clinical trial groups in recent decades, there has been a significant improvement in their cure rates.
Patients & Methods:
From January 2001 till December 2015, retrieval & analysis of the medical records of pediatric patients with genitourinary tumors will be made at the pediatric oncology department, South Egypt Cancer Institute which represents the largest referral center in Upper Egypt. These data will be categorized according to demographic characteristics, clinico-pathologic features, treatment modalities received, and outcomes of treatments in these patients.
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||March 2021|
|Estimated Study Completion Date :||April 2021|
- Overall survival (OS) [ Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years ]Time from the date of initiation of treatment until death from any cause
- Event Free Survival (EFS) [ Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years ]Time from the date of initiation of treatment until disease progression, or death for any reason.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02557230
|Assiut, Egypt, 71515|
|Contact: Ahmed M. Morsy, MD +2 01003314522 firstname.lastname@example.org|
|Principal Investigator: Ahmed M. Morsy, MD|
|Principal Investigator: Khalid M. Rezk, MD|
|Principal Investigator: Badawy M. Ahmed, MD|
|Principal Investigator: Ameer M. Abuelgheet, MD|